Platelets have long been dismissed as simple clotting agents, fragments of megakaryocytes whose job is to plug wounds. Over the past decade, however, they have been recast as sophisticated sentinels of disease. Tumors educate platelets: they release vascular endothelial growth factor and other pro-angiogenic signals, shield circulating tumor cells from immune attack, and swap molecular information with the tumor microenvironment. Because platelets internalize and process RNA from the conditions they encounter, their transcriptome acts as a circulating diary of systemic illness. The new study, published in Cancer Reports, revisits publicly available platelet RNA-sequencing data from 84 treatment-naive glioblastoma patients and 319 healthy controls, refining the original cohort by excluding astrocytoma grade IV cases to match the WHO 2021 definition of glioblastoma as an IDH-wildtype grade 4 diffuse astrocytic tumor, and removing a small batch of control samples affected by a technical artifact.

The analytical design is what makes the study interesting to computational biologists. Rather than relying on a single method, the team ran two deliberately different approaches on the same dataset of 4,412 expressed genes. The first, Gene Set Enrichment Analysis, or GSEA, ignores arbitrary significance cutoffs and instead ranks the entire transcriptome, asking whether known biological pathways shift in a coordinated way between patients and controls. The second, threshold-based differential expression analysis followed by Elastic Net regularization, is a machine learning workflow: DESeq2 first narrows thousands of genes to 323 candidates with fold changes above 1.3 and a false discovery rate below 0.1, and then a penalized logistic regression model shrinks most coefficients to zero, retaining only the most informative predictors. The result was a compact 103-gene signature that distinguishes glioblastoma from healthy blood with striking accuracy.

That accuracy is the headline number. Evaluated on an independent test set kept completely separate during model development, the 103-gene platelet signature achieved an area under the curve of 0.99 with a misclassification rate of just five percent. Across ten random repetitions of the entire procedure, the mean AUC held at 0.989, with mean sensitivity of 0.877 and specificity of 0.980. Crucially, the team did not stop there. They compared their signature against 100 randomly generated 103-gene panels, and while random genes also performed surprisingly well in this high-dimensional setting, the real signature consistently outperformed the random reference distribution in both AUC and balanced accuracy. In an additional external platelet RNA cohort, without any genome-wide feature selection, the signature still achieved an AUC of 0.93, evidence that the signal is at least partly transferable across laboratories and sequencing pipelines.

The GSEA arm of the study tells a different, more mechanistic story. Positively enriched pathways in patients clustered around core platelet biology: blood coagulation, platelet activation, wound healing, vascular and circulatory processes, cytoskeletal organization, and extracellular matrix remodeling. To tame the redundancy inherent in Gene Ontology terms, the researchers applied a Markov clustering framework, grouping the enriched terms into 22 clusters that spanned vascular processes, RNA processing, ribosomal function, immune regulation, autophagy, and cellular metabolism. Because GSEA results can depend on the random seed, the entire enrichment analysis was repeated ten times with different seeds, and the top pathways proved highly consistent across iterations. Notably, transcripts associated with ribosomal function and protein synthesis were downregulated in patient platelets, echoing earlier reports of suppressed translation-related programs in tumor-educated platelets.

Perhaps the most puzzling finding was the enrichment of bacterial response pathways in the predictive gene signature, given that none of the patients showed signs of infection when their blood was drawn. The authors propose a plausible explanation rooted in damage-associated molecular patterns, or DAMPs. Necrotic cells deep inside glioblastoma release these molecules, which activate Toll-like receptors on platelets and effectively mimic the molecular alarm signals that bacteria trigger. In other words, a tumor that never hosted an infection can still make the platelet transcriptome look as if one were raging. This sterile-inflammation mechanism could help explain the chronic inflammatory tone that glioblastoma cultivates systemically, and it fits with the description of tumors as wounds that refuse to heal, perpetually regenerating tissue that recruits myeloid cells, fuels angiogenesis, and remodels the extracellular matrix.

The predictive genes themselves sketch a portrait of immune and cellular dysfunction. Elevated transcripts included B2M and LGALS2, both implicated in immune evasion, while downregulated genes such as CXCR2P1 and OAS1 hint at blunted anti-tumor interferon responses. Genes tied to proliferation, including CAMK2D and PIK3IP1, to metabolism, including MAOB and FKBP5, and to epigenetic regulation, such as the chromatin factor CBX7, round out the panel. The authors are careful to stress a critical caveat: Elastic Net selects genes for predictive power, not proven mechanism, and the Gene Ontology analysis of the 103-gene panel yielded no terms surviving multiple-testing correction, so the functional annotations attached to the signature are explicitly descriptive rather than definitive evidence of pathway overrepresentation.

To test whether the strongest platelet signals reflect anything real about the tumor microenvironment, the team turned to independent glioma datasets. In bulk RNA data spanning multiple glioma grades, platelet activation and aggregation signatures correlated strongly with wound healing signatures, and wound healing programs were elevated in glioma patients compared with normal controls. Single-cell RNA sequencing data analyzed with a pseudobulk approach confirmed the pattern on two different platforms, 10x Genomics and SMART-Seq, with the correlation between platelet activation and wound healing scores appearing even stronger in the SMART-Seq samples. Because high-quality external platelet RNA cohorts remain scarce, this cross-dataset triangulation is supportive rather than a direct replication, but it suggests that the platelet transcriptome is genuinely tracking tumor-associated biology rather than laboratory noise.

The study is candid about its limits. The cohort, though large by platelet RNA standards, still contains a modest number of glioblastoma cases; the thresholds used for gene selection are conventional rather than biologically derived; and clinical annotation was too incomplete to rule out confounding by medications or other conditions that also reprogram platelets. Many platelet activation signatures are shared across cancers and inflammatory diseases, so the findings cannot be treated as glioblastoma-specific without further validation, and pathway annotations curated from nucleated cells must be interpreted cautiously when applied to anucleate platelets. Even so, the work demonstrates that a routine blood draw, read through the right computational lens, can reveal coordinated systemic responses to one of medicine’s most formidable tumors, and it lays a concrete foundation for larger, fully annotated studies that could one day turn tumor-educated platelets into a non-invasive diagnostic and monitoring tool for brain cancer.

Subject of Research: Platelet-derived RNA biomarkers for glioblastoma detection

Article Title: Deepening the Understanding of Platelet‐Derived RNA as Biomarker for Glioblastoma Through GSEA, TDEA, and Elastic Net Regularization Analysis

Article References: Giczewska, A., Pastuszak, K., van Hout, L., Post, E., Ramaker, J., Zwaan, K., Supernat, A., & Westerman, B. A. (2026). Deepening the Understanding of Platelet‐Derived RNA as Biomarker for Glioblastoma Through GSEA , TDEA , and Elastic Net Regularization Analysis. Cancer Reports, 9(10), Article e70656. https://doi.org/10.1002/cnr2.70656

Image Credits: AI Generated

DOI: 10.1002/cnr2.70656

Keywords: glioblastoma, platelet RNA, tumor-educated platelets, liquid biopsy, GSEA, Elastic Net, biomarker, RNA sequencing, tumor microenvironment, DAMPs, machine learning, blood-based diagnostics

The clinical burden that motivates this push is substantial. Bladder cancer, the most common form of urothelial carcinoma, is characterized by high rates of late diagnosis and strikingly frequent recurrence, forcing patients into years of repeated surveillance procedures. Cystoscopy, the endoscopic examination of the bladder that remains the diagnostic gold standard, is uncomfortable, expensive and offers only a visual snapshot of the tumor at a single moment in time. Tissue biopsy, meanwhile, samples only a fragment of the lesion, leaving the considerable spatial heterogeneity of the disease hidden from view. Neither approach lends itself naturally to the kind of longitudinal monitoring that bladder cancer patients, who face lifelong recurrence risk, genuinely require. It is precisely these constraints, the review argues, that have created the opening for liquid biopsy to move from research curiosity to clinical mainstay.

At the heart of the liquid biopsy concept are three principal analytes: circulating tumor DNA, circulating tumor cells and extracellular vesicles. Circulating tumor DNA consists of short fragments of tumor genome shed into the bloodstream, carrying with them the mutations, copy number variations and methylation patterns that define the original malignancy. Because it can be sampled repeatedly through a simple blood draw, ctDNA offers a dynamic, real-time portrait of tumor burden and evolution. The review details how technological advances, including droplet digital PCR and next-generation sequencing, have progressively lowered the detection limits for these faint molecular signals, enabling clinicians to identify residual disease at levels far below what imaging or cytology can resolve.

Circulating tumor cells, the second pillar, provide something ctDNA cannot: intact living cells that retain their morphology, protein expression and functional behavior. These cells, which detach from the primary tumor and travel through the circulation, are thought to be the seeds of metastasis. Capturing and characterizing them allows researchers to interrogate the epithelial-to-mesenchymal transition, the process by which cancer cells acquire invasive and migratory properties, and to profile the cell surface markers that may predict how aggressive a given patient’s disease will become. The review emphasizes that CTC enumeration and molecular characterization hold particular promise for prognostic stratification, helping to separate patients at high risk of progression from those who may be spared aggressive intervention.

Extracellular vesicles, the third and perhaps most versatile analyte, are nanoscale membrane-bound particles released by tumor cells into their surroundings. Far from being cellular debris, these vesicles act as intercellular messengers, ferrying proteins, lipids and nucleic acids between cells and actively shaping the tumor microenvironment. Within them travel microRNAs, long non-coding RNAs and circular RNAs, a cargo of regulatory molecules whose signatures can reveal both the presence of cancer and the state of the immune response against it. The review also highlights tumor-educated platelets, blood platelets that have been reprogrammed by tumor-derived signals and whose RNA profiles offer an additional, largely tumor-independent window into disease status.

What unites these analytes is their application across the entire arc of cancer care. In early detection, urine-based and blood-based biomarker panels are being developed to identify urothelial carcinoma before it becomes symptomatic, potentially reducing dependence on repeated invasive surveillance in patients with a history of the disease. In prognostic stratification, the review consolidates evidence linking ctDNA levels, CTC counts and vesicle cargo to progression-free and overall survival, suggesting that a single blood draw could one day inform how intensively a newly diagnosed patient is treated. In treatment response monitoring, serial liquid biopsy measurements can reveal whether neoadjuvant chemotherapy is working within weeks of initiation, long before radiographic scans could show any change, allowing ineffective regimens to be abandoned and alternatives started sooner.

The review gives particular attention to the intersection of liquid biopsy with immunotherapy, an area of intense clinical interest in metastatic urothelial carcinoma. Immune checkpoint inhibitors have reshaped treatment for advanced disease, but only a subset of patients respond, and clinicians currently lack reliable tools to identify responders in advance. Liquid biopsy offers several routes into this problem: ctDNA dynamics during therapy appear to correlate with response and survival, while the molecular features of circulating analytes can be used for immunophenotyping, characterizing the inflammatory and immune landscape of the tumor without touching it. The authors argue that such non-invasive immunophenotyping could eventually guide the selection of patients for checkpoint inhibitor therapy and for emerging combinations, moving the field closer to truly individualized immunotherapy decisions.

None of this, the review is careful to stress, is yet a finished story. Significant challenges persist before liquid biopsy can be integrated routinely into bladder cancer management. Analytical hurdles include the low fraction of tumor-derived DNA in early disease, the lack of standardized protocols for sample collection, processing and quality control, and variability among the many sequencing and capture platforms now on the market. Clinical hurdles include the absence of large, prospective, multicenter validation trials demonstrating that liquid biopsy-guided decisions genuinely improve patient outcomes, and unresolved questions about which analyte, or which combination of analytes, delivers the greatest value for each clinical scenario. Cost and accessibility also remain concerns if the technology is to benefit patients beyond specialized academic centers.

The translational path forward, as the authors outline it, involves converging several emerging technologies. Machine learning algorithms are increasingly being applied to multi-analyte datasets to extract diagnostic and prognostic signals that no single marker could provide, and whole-genome sequencing approaches are expanding the range of detectable alterations beyond the hotspots targeted by conventional panels. The review envisions a future in which a bladder cancer patient’s trajectory, from initial suspicion through treatment and into long-term surveillance, is punctuated not by repeated cystoscopies but by serial molecular snapshots drawn from blood and urine, with minimal residual disease detected and treated before it ever becomes visible on a scan.

For a disease defined by recurrence and heterogeneity, the appeal of that vision is easy to understand. The review’s synthesis makes the case that the scientific groundwork, sensitive detection platforms, biologically informative analytes and accumulating clinical evidence, has largely been laid. What remains is the disciplined work of validation, standardization and integration into treatment guidelines. If that work succeeds, liquid biopsy could shift bladder cancer care from a reactive cycle of detection and resection toward a proactive, molecularly informed model of precision oncology, in which each patient’s therapy is continuously calibrated to the evolving biology of their tumor, sampled not with a scalpel but with a needle and a vial.

Subject of Research: Liquid biopsy biomarkers for early detection, monitoring and precision treatment of bladder cancer

Article Title: Liquid biopsy in bladder cancer: towards precision oncology

Article References: Chen, C., Yang, Y., Chen, Z., Li, X., Zhu, Y., Zhai, Y., Zheng, J., Dai, X., Zhou, J.-G., Ma, H., & Ye, X. (2026). Liquid biopsy in bladder cancer: towards precision oncology. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08892-7

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08892-7

Keywords: liquid biopsy, bladder cancer, urothelial carcinoma, circulating tumor DNA, circulating tumor cells, extracellular vesicles, precision oncology, minimal residual disease, immune checkpoint inhibitors, tumor-educated platelets, next-generation sequencing, biomarkers